<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0266262</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5187</journal-id>
<journal-id journal-id-type="nlm-ta">J Physiol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Physiol. (Lond.)</journal-id>
<journal-title-group>
<journal-title>The Journal of physiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-3751</issn>
<issn pub-type="epub">1469-7793</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31045243</article-id>
<article-id pub-id-type="pmc">7087452</article-id>
<article-id pub-id-type="doi">10.1113/JP277651</article-id>
<article-id pub-id-type="manuscript">NIHMS1572910</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Potentiating α<sub>2</sub> subunit containing perisomatic GABA<sub>A</sub> receptors protects against seizures in a mouse model of Dravet Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nomura</surname>
<given-names>Toshihiro</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hawkins</surname>
<given-names>Nicole A.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kearney</surname>
<given-names>Jennifer A.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>George</surname>
<given-names>Alfred L.</given-names>
<suffix>Jr</suffix>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Contractor</surname>
<given-names>Anis</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<aff id="A1"><label>1</label>Department of Physiology, Northwestern University, Chicago, IL 60611</aff>
<aff id="A2"><label>2</label>Department of Pharmacology Feinberg School of Medicine and, Northwestern University, Chicago, IL 60611</aff>
<aff id="A3"><label>3</label>Department of Neurobiology Weinberg College of Arts and Sciences, Northwestern University, Chicago, IL 60611</aff>
</contrib-group>
<author-notes>
<corresp id="CR1">Correspondence: Anis Contractor, PhD, Department of Physiology, Northwestern Feinberg School of Medicine, Chicago, IL 60611, <email>a-contractor@northwestern.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>20</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>23</day>
<month>3</month>
<year>2020</year>
</pub-date>
<volume>597</volume>
<issue>16</issue>
<fpage>4293</fpage>
<lpage>4307</lpage>
<!--elocation-id from pubmed: 10.1113/JP277651-->
<abstract id="ABS1">
<p id="P1">GABA<sub>A</sub> receptor potentiators are commonly used for the treatment of epilepsy, but it is not clear whether targeting distinct GABA<sub>A</sub> receptor subtypes will have disproportionate benefits over adverse effects. Here we demonstrate that the α<sub>2</sub> / α<sub>3</sub> selective positive allosteric modulator (PAM) AZD7325 preferentially potentiates hippocampal inhibitory responses at synapses proximal to the soma of CA1 neurons. The effect of AZD7325 on synaptic responses was more prominent in mice on the 129S6/SvEvTac background strain that have been demonstrated to be seizure resistant in the model of Dravet syndrome (<italic>Scn1a</italic><sup>+/−</sup>), and in which the α<sub>2</sub> GABA<sub>A</sub> receptor subunits are expressed at higher levels relative to in the seizure prone C57BL/6J background strain. Consistent with this, treatment of <italic>Scn1a</italic><sup>+/−</sup> mice with AZD7325 elevated the temperature threshold for hyperthermia-induced seizures without apparent sedative effects. Our results in a model system indicate that selective targeting α<sub>2</sub> is a potential therapeutic option for Dravet syndrome.</p>
</abstract>
<kwd-group>
<kwd>GABA receptor</kwd>
<kwd>α<sub>2</sub> subunit</kwd>
<kwd>Dravet syndrome</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>